THE MEDICINES PATENT POOL AND GILEAD SCIENCES SIGN LICENCE FOR BICTEGRAVIR
The MPP announced on 4 October 2017 a licence with Gilead Sciences for bictegravir (BIC), now under review in the United States and the European Union as part of a once-daily, single-tablet HIV regimen.
BRISTOL-MYERS SQUIBB, MEDICINES PATENT POOL EXTEND LICENCE FOR ATAZANAVIR TO 122 DEVELOPING COUNTRIES
The MPP has signed an extension of its licensing agreement with biopharmaceutical company Bristol-Myers Squibb (BMS) to further increase access to atazanavir (ATV), part of the World Health Organization-preferred second-line treatment for adults and children.
First step in Upgrading Resource to Include All Patented Treatments on the World Health Organization’s Essential Medicines List
Geneva, 12 December 2017 — The Medicines Patent Pool today announced the expansion of MedsPaL, a comprehensive resource for information on the intellectual property status of priority medicines in developing countries, to patented treatments on the World Health Organization (WHO)’s Model List of Essential Medicines (EML). Data on patents for certain medicines to treat chronic myeloid leukaemia, breast cancer and other cancer indications have been added to its HIV, hepatitis C and tuberculosis medicine database. MedsPaL now covers 6,800 national patent applications in more than 110 countries for more than 70 priority treatments.
“Simplified access to accurate patent information on medications that meet important needs in national health systems is imperative,” said Greg Perry, Executive Director of the Medicines Patent Pool. “We are pleased to augment the content of MedsPaL to en...
Geneva, 6 December 2017 — The Medicines Patent Pool Governance Board has appointed Patrizia Carlevaro, co-founder of the technology company GenomSys, as a new board member, effective 1 December. Dr. Carlevaro, formerly Managing Director of Otsuka and Head of the International AID Unit at Eli Lilly and Company in Geneva, has had a long, distinguished career in public health, specifically in the research and development-based pharmaceutical industry. At Otsuka, she was responsible for subsidiary operations and the anti-infective business unit’s public health projects. At Lilly, where she served for almost a decade, Dr. Carlevaro developed and managed the company’s global Multidrug-Resistant Tuberculosis (MDR-TB) Partnership programme, conducting transfer of technology programmes for TB compounds to local manufacturers in China, India, South Africa and Russia.
“We are pleased to welcome Patrizia to the MPP Governance Board,” said Marie-Paule Kieny, Chair of the Board. “With her many years of experience in pha...
1 December 2017
Greg Perry, Executive Director
This World AIDS Day, we are pleased to acknowledge the international community’s progress in ensuring that people living with HIV have the tools necessary to lead long, healthy lives. Last week, UNAIDS reported a record 20.9 million people are now accessing antiretroviral therapy, a threefold increase since Unitaid created the MPP in 2010 to support the HIV response. The MPP is proud of the part it has played over the years to improve the availability of low-cost, high-quality medicines in low- and middle-income countries. To date, our generic partners have distributed more than five billion doses of WHO-recommended antiretrovirals, the equivalent of 14 million patient years of treatment.
This past year, we also welcomed our partners steps to produce, register and rollout new HIV treatment regimens that could be game changers in advancing standard of care. Sixteen companies are currently developing new HIV treatment dolutegravir (DTG), an easily admi...
“Successful cooperation of the Ministry of Health of Belarus with the Medicines Patent Pool is crucial in light of our current work to achieve the “90-90-90” goals and put an end to the epidemic in the country which is only possible when access to affordabl...”